1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Gufic Biosciences Limited

Gufic Biosciences Limited

391.80
INR
-2.20
(-0.56%)
7.32EPS
55.59P/E
40.82BMarket Cap
Gufic Biosciences Limited
NSE:GUFICBIO
(National Stock Exchange of India)

Recent

price

391.80

P/E

ratio

55.59

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
9.24
10.22
12.28
14.96
18.84
25.29
31.04
38.32
44
39.08
50.31
73.55
70.12
78.12
74.35
81.04
97.8
Revenue per Share
0.19
0.2
0.43
0.55
0.54
0.95
1.17
2.12
2.82
2.34
4.56
9.89
8.22
8.74
6.95
6.4
7.32
Basic EPS, GAAP
-0.15
0.24
-1.05
0.9
1.12
-0.68
-1.07
-1.68
-1.01
0.75
7.72
1.94
-22.09
-12.2
4.69
1.39
- -
Free Cash Flow per Basic Share
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.1
0.11
0.1
0.1
0.1
- -
Dividend per Share
2.38
2.52
2.9
3.39
3.5
3.72
4.83
7
9.68
16.62
17.89
27.76
35.88
53.11
59.94
66.31
- -
Book Value per Share
2.28
2.47
2.89
3.38
3.5
3.72
4.82
6.94
9.63
16.54
17.84
27.7
35.81
52.55
59.31
65.69
- -
Tangible Book Value per Share
77
77
77
77
77
77
77
78
78
97
97
97
97
99
100
100
100
Basic Weighted Avg Shares
715
791
950
1,157
1,457
1,956
2,401
2,982
3,424
3,788
4,877
7,130
6,798
7,697
7,456
8,127
9,811
Sales/Revenue/Turnover
5.76
7.12
9.71
8.38
7.45
8.45
8.02
11.62
12.28
10.46
13.97
18.11
16.97
17.23
15.74
14.83
13.64
Operating Margin (%)
18
19
22
25
39
38
37
44
46
139
163
189
223
170
211
308
308
Depreciation Expense
15
15
33
43
42
73
90
165
219
227
442
958
797
861
696
642
735
Net Income, GAAP
38.24
48.58
36.74
32.03
36.29
29.29
37.21
44.99
37.93
24.69
23.36
24.44
25.31
25.53
26.02
25.81
26.04
Effective Tax Rate (%)
2.05
1.93
3.51
3.69
2.85
3.74
3.76
5.52
6.41
5.99
9.07
13.44
11.73
11.19
9.34
7.9
7.49
Profit Margin (%)
60
39
66
90
79
87
151
297
462
335
969
1,344
1,759
2,284
2,370
2,843
- -
Working Capital
53
43
184
149
115
75
66
83
113
257
382
483
2,069
1,655
1,501
1,194
- -
LT Debt
184
195
224
262
271
288
373
541
753
1,293
1,734
2,691
3,478
5,326
6,011
6,650
- -
Total Equity
3.82
3.43
6.23
6.44
6.17
11.1
12.44
17.13
17.12
14.03
21.43
34.52
16.99
12.53
9.68
8.96
- -
Return on Invested Capital (%)
4.08
6.83
11
11.83
11.68
17.76
15.64
18.65
18.35
15.03
21.7
34.78
16.67
12.55
9.62
9
- -
Return on Capital (%)
8.17
8.05
15.89
17.55
15.6
26.22
27.29
36.03
33.89
22.17
29.22
43.31
25.84
19.57
12.29
10.14
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
2,853
- -
LT Borrowings
- -
1,050
- -
LT Finance Leases
- -
144
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
100
Market Capitalization
33,695
27,457
40,820

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
8,021
- -
Cash, Cash Equivalents & STI
- -
762
- -
Accounts Receivable, Net
- -
2,974
- -
Inventories
- -
3,245
- -
Total Current Liabilities
- -
5,178
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
2,853
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.07%
32.21%
10.63%
Free Cash Flow
-75.37%
-313.68%
-70.33%
Net Income, GAAP
31.83%
16.19%
-7.8%
Sales/Revenue/Turnover
16.18%
12.13%
9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2,028
2,042
2,078
2,050
7,456
2026
2,237
2,371
2,314
2,518
8,127
2027
2,608
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.08
2.17
1.93
0.77
6.95
2026
1.3
1.68
1.24
2.18
6.4
2027
2.22
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.1
2026
- -
- -
- -
- -
0.1
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Gufic Biosciences Limited is an India-based pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), herbal formulations, and consumer personal care products. Its core products include lyophilized injections across therapeutic segments such as antibiotics, antifungals, cardiac medicines, infertility treatments, antivirals, proton pump inhibitors, critical care medicines, and nutraceuticals. The company produces pharmaceutical formulations in various dosage forms including injectables, syrups, ointments, lotions, tablets, capsules, and herbal products, serving over 15 therapeutic areas with a portfolio of more than 100 products and 200 stock-keeping units (SKUs). Gufic Biosciences is one of the largest manufacturers of lyophilized injections in India and operates a fully automated robotic-armed lyophilization plant. It also manufactures consumer personal care items such as sanitary napkins and anti-stretch mark creams. The company has a research and development pipeline focused on complex injectables, biologicals, immuno-oncology, assisted reproductive technology therapies, toxins, and science-based nutraceuticals. Founded in 1970 and headquartered in Mumbai, India, Gufic Biosciences has expanded its operations internationally, with subsidiaries including Gufic Ireland Limited and a presence in countries like Australia, Mexico, South Africa, the Philippines, Thailand, and Nepal. Recent strategic developments include additional investments in subsidiaries and funding for Gufic Ireland Limited, expansion of the product pipeline with over 50 products under development targeting regulated and semi-regulated markets, and forthcoming approval for Immunocin-Alpha, an innovative immunotherapy for sepsis. The company recently launched new senior management appointments to strengthen its critical care and fertility business units. Gufic continues to focus on expanding its global reach with over 150 products in registration pipelines across more than 30 countries, enhancing its presence in critical care, fertility, nutraceuticals, and aesthetic and derma solutions. Gufic Biosciences maintains a leadership position in specialized medicinal segments by leveraging its innovation in lyophilization technology and a diversified product portfolio spanning pharmaceutical formulations, bulk drugs, and herbal formulations. The company's products are supplied to major hospital chains and medical facilities across India and abroad. Its business segments include domestic branded formulations, contract manufacturing, and exports with a strong emphasis on research and regulatory compliance. The company’s mission centers on making high-quality, cost-effective pharmaceutical products widely accessible while advancing innovation in specialized medical therapies and formulations.